Congress hands President blank check to pay pharma companies for 'national defense'
H.R. 7777 — Protecting America’s Medical Supply Chains Act of 2026 · Filed by Maria Salazar (R-FL) · Introduced Mar 3, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends the Defense Production Act of 1950 to give the President broad authority to secure medical supply chains (drugs, devices, biologics) deemed essential to national defense. It requires the President to submit a strategy within 180 days identifying vulnerabilities, diversifying suppliers, and ensuring no foreign government has exclusive control of critical medical components. It also authorizes direct payments to U.S. companies that produce critical medical components or raw materials, if the President certifies the payment is necessary for national defense—with minimal congressional oversight (30-day notice only).
Why we flagged it
The bill's core function is to expand presidential authority under the Defense Production Act to direct federal payments to private medical-supply companies under a 'national defense' rationale, with unusually broad definitional discretion delegated to the executive branch and minimal congressional oversight.
What the text implies
- The definition of 'supply chain activities' is delegated entirely to the President by regulation, with no statutory bounds. This allows the executive to expand the scope of eligible recipients far beyond traditional pharmaceutical manufacturers to include logistics, packaging, data services, or other tangentially related entities.
- The 30-day notice requirement for payments is not a veto—Congress cannot block the payment, only be informed. This is weaker than standard appropriations oversight and creates a de facto executive spending authority.
The full analysis lists 5 implications of this text.
Who stands to gain
pharmaceutical manufacturers; medical device companies; biological product manufacturers